Treatment with systemic immunostimulatory agents within  weeks or  half-lives of the drug, whichever is longer, prior to initiation of study treatment
Treatment with systemic immunostimulatory agents within  weeks or five half-lives of the drug (whichever is longer) prior to randomization
Treatment with systemic immunostimulatory agents within  weeks or five half-lives of the drug, whichever is shorter, prior to enrollment
Treatment with systemic immunostimulatory agents;
Treatment with systemic immunostimulatory agents within  weeks or five half-lives of the drug, whichever is shorter, prior to enrollment (with the exception of checkpoint blockade therapy)
Patients who receive treatment with systemic immunostimulatory agents (including but not limited to IFNs, IL-) within  weeks or five half-lives of the drug, whichever is shorter, prior to study registration are not eligible
Treatment with systemic immunostimulatory agents within  weeks or five half-lives of the drug, whichever is shorter, prior to initiation of study treatment
Treatment with systemic immunostimulatory agents within  weeks or  half-lives of the drug, whichever is longer, prior to Cycle , Day 
Treatment with systemic immunostimulatory agents (including but not limited to interleukin-) within  weeks or five half-lives of the drug, whichever is shorter, prior to first dose.
Treatment with systemic immunostimulatory agents within  weeks or five half-lives of the drug, whichever is shorter, prior to first dosing.
Treatment with systemic immunostimulatory agents within  weeks or five half-lives of the drug (whichever is shorter) prior to randomization
Receiving systemic immunostimulatory agents within  weeks or  half-lives, whichever is shorter, prior to first dose of study treatment (except ant PD-/PD-L treatment if recruited into Group a or b).
Treatment with systemic immunostimulatory agents within  weeks or  half-lives of the drug (whichever is longer) prior to enrollment
Treatment with systemic immunostimulatory agents
Treatment with systemic immunostimulatory agents within  weeks or five half-lives of the drug, whichever is shorter, prior to the first dose of study treatment
Treatment with immunostimulatory agents within  weeks or immunosuppressive agents within  weeks prior to randomization
Treatment with systemic immunostimulatory agents within  weeks or five half-lives of the drug, whichever is longer, prior to screening
Treatment with systemic immunostimulatory agents
